Leading law firm, WilmerHale, provides counsel to RA Capital, acting as prominent investor, in a $175 million private placement funding round for biotech company, SAB BIO.
SAB BIO, a clinical-stage biopharmaceutical company, announced a significant private placement financing of $175 million on July 21, 2025. This funding round will aid the company in its mission to develop therapies for delaying the progression of Type 1 diabetes in newly diagnosed autoimmune T1D patients.
The financing event involved the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at $1.75 per share. The securities purchase agreement also includes an option for investors to purchase additional shares of the Company's Series B nonvoting convertible preferred stock for up to an additional $284 million.
The institutional investors participating in this round include RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners, Woodline Partners LP, as well as existing investors Sessa Capital, the T1D Fund, and ATW Partners. The strategic investor Sanofi also participated in the financing.
WilmerHale, a law firm, provided legal representation for one of the investors in the SAB BIO financing. The financing team at WilmerHale was led by Chris Barnstable-Brown and Scott Lunin, and included members such as Chris Barnstable-Brown, Scott Lunin, and Frank Wang. WilmerHale represented lead investor RA Capital Management in the SAB BIO financing, and RA Capital Management was also represented by WilmerHale in the transaction.
The private placement will be used to advance the development of SAB BIO's pipeline of potential therapies for Type 1 diabetes. The proceeds are intended to fund the Phase 2b SAFEGUARD study for delaying progression of autoimmune Type 1 Diabetes and extend the company's cash runway into mid-2028.
This financing is a significant step forward for SAB BIO, providing the company with substantial funds to continue its work in the development of therapies for Type 1 diabetes. The company is listed on Nasdaq under the ticker symbol SABS.
This private placement is not an advertisement but a factual report about the financing event involving SAB BIO. The private placement was oversubscribed, indicating strong investor confidence in the company's potential to make a significant impact in the treatment of Type 1 diabetes.
[1] SAB BIO Press Release, "SAB BIO Secures $175 Million in Private Placement Financing," July 21, 2025. [2] BusinessWire, "SAB BIO Secures $175 Million in Private Placement Financing," July 21, 2025. [3] GlobeNewswire, "SAB BIO Secures $175 Million in Private Placement Financing," July 21, 2025.
The significant private placement financing of $175 million will be utilized by SAB BIO to advance the development of its pipeline of potential therapies for Type 1 diabetes, specifically funding the Phase 2b SAFEGUARD study for delaying the progression of autoimmune Type 1 Diabetes and extending the company's cash runway into mid-2028. This financial event, which involved the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock, demonstrates strong investor confidence in the company's potential to make a significant impact in the treatment of Type 1 diabetes.
